Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%
Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the ...
Fierce Pharma4d
Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts
News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...
Citi remains ‘very bullish’ on Gilead HIV franchise
HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...
Citi “Very Bullish” on Gilead’s (NASDAQ:GILD) HIV Business
Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...
pharmaphorum5d
Gilead strikes deal to expand HIV drug access in 120 countries
Gilead Sciences has taken a major step towards increasing ... paving the way for increased production and distribution of lenacapavir, its long-acting HIV prevention medication, in 120 high ...
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.
Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...
pharmaphorum4d
Merck halts more trials of HIV candidate islatravir
A few days later, confidence in the drug was dented again when Gilead Sciences called a halt to a mid-stage trial of islatravir given alongside its HIV capsid inhibitor lenacapavir, which is ...
Yahoo Finance6d
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.